Elsevier

Medical Hypotheses

Volume 160, March 2022, 110774
Medical Hypotheses

Correspondence
Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis

https://doi.org/10.1016/j.mehy.2022.110774Get rights and content

Abstract

Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.

Keywords

Diethylcarbamazine
Drug repurposing
Pulmonary fibrosis
COVID-19-related pulmonary fibrosis
Post-COVID-19

Cited by (0)

View Abstract